How fast is fast enough? That’s a question to pose to Amazon, which is kicking its already brisk deliveries into high gear with one-hour and three-hour shipping across select U.S. cities, including Chicago, Los Angeles, Nashville and Washington, D.C., in its latest bid to leave the competition in the dust. “Our customers are busier than ever and are looking for new ways to save time while keeping their households running,” Udit Madan, senior vice president of worldwide operations at the e-tail Goliath, s ...

Core Insights - Future has launched Helix, a next-generation audience intelligence engine aimed at enhancing commercial outcomes for advertisers [1] - Helix integrates advanced data science and predictive AI with Future's extensive first-party data to connect brands with high-value audiences at the moment of purchase intent [2] Group 1: Helix Overview - Helix represents the evolution of Future's proprietary audience data platform, Aperture, which was launched in 2021 [3] - The Helix engine is built on three strategic pillars, focusing on identifying audiences that will drive results and measuring their impact throughout the purchase journey [3] Group 2: Performance Metrics - Initial testing of Helix across 20 major campaigns in sectors such as fashion, retail, and technology demonstrated double-digit increases in Click-Through Rates (CTR), leading to significant improvements in Return on Ad Spend (ROAS) compared to traditional methods [3] Group 3: Market Launch and Features - Helix is currently being launched in the U.S. market, with plans for a rollout in the UK market at a later date [4] - The engine includes features such as real-time intent mapping, audience segment recommendations based on conversion behavior, and a Performance Pledge that guarantees CTR for early-access U.S. advertisers [4]

Financial Data and Key Metrics Changes - Fourth quarter 2025 revenue totaled $14.3 million, a decrease of $11.9 million or 46% compared to the fourth quarter of 2024 [22] - Full year 2025 revenue increased to $86.2 million compared to $83.8 million in 2024, driven by strong performance in the first half of the year [24] - Gross profit for the fourth quarter was $9.5 million, a decrease of $12.3 million or 56% from the fourth quarter of 2024 [23] - Full year 2025 gross margin was 74.5% compared to 85.6% in 2024 [25] - Net loss for the quarter was $594,000 or $0.04 per share, while the full year net loss was $5.1 million, an improvement of $667,000 compared to the net loss of $5.8 million in 2024 [24][27] Business Line Data and Key Metrics Changes - Operating expenses for the fourth quarter were $10.7 million, down more than 50% compared to the fourth quarter of 2024, primarily due to a 60% year-over-year decrease in marketing expenses [23] - Full year 2025 operating expenses were $70.9 million, down $6.4 million or 8% from 2024 [26] - The company acquired 83 new clients in 2025, reflecting improved retention quality and higher average budget commitments [16] Market Data and Key Metrics Changes - The company is beginning to see recovery in revenue after a low point in mid-January, with expectations for gradual recovery throughout 2026 [28] - Strong double-digit growth is forecasted for each quarter of 2026, driven by a healthy sales pipeline [28] Company Strategy and Development Direction - The company aims to leverage its IntentKey technology to pursue high-margin growth and establish a more resilient business model [10] - Four strategic pillars include refined go-to-market focus, raising IntentKey's industry profile, continuous product innovation, and high-margin growth [10][12][15] - The company is focusing on high-potential verticals such as life sciences, pharmaceuticals, healthcare, automotive, and government [36] Management's Comments on Operating Environment and Future Outlook - The industry is experiencing a shift due to emerging technologies and increased regulation, creating a ripe environment for disruption [7] - Management believes that IntentKey provides a significant competitive advantage in the evolving programmatic landscape [12] - The company is optimistic about its growth potential and is taking steps to enhance brand awareness and market presence [31] Other Important Information - The company is migrating its data centers to AWS cloud for cost savings and scalability [19] - A new product-specific website for IntentKey will be launched to support sales teams and encourage self-service trials [16] Q&A Session Summary Question: Capital deployment strategy between existing businesses and new data offering - Management indicated that marketing expenses are variable and tied to sales velocity, with a focus on demand creation for IntentKey [34] Question: Plans to improve awareness of IntentKey - Management plans to raise IntentKey's profile through thought leadership, industry presence, and targeted marketing in high-potential verticals [35] Question: Revenue expectations and expense management - Management expects revenue to increase gradually, with careful management of expenses, particularly in marketing [39][41] Question: IntentKey self-serve product's role in growth roadmap - Management views the self-serve product as a longer-term ambition that will contribute to revenue growth over time [45] Question: Relationship with Google and contract extensions - Management emphasized the importance of maintaining quality and compliance to uphold relationships with key partners like Google [52] Question: Status of a potential government contract - Management confirmed that a multi-year, multi-million dollar government contract is in the final stages and expected to be executed soon [58]

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% increase compared to 2024 [17][18] - Gross margin for Q4 was 70.9%, up 90 basis points year-over-year, while full year gross margin was 70.6%, an improvement of 170 basis points [18] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million [19] - Adjusted EBITDA for Q4 was $34.3 million, representing 16.4% of revenue, and for the full year, it was $68.9 million, or 9.2% of revenue, marking a significant improvement [20] Business Line Data and Key Metrics Changes - Growth in Q4 was driven by sustained volume demand across all channels, with new store growth accounting for approximately 68% of year-over-year volume growth [17][18] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [10][11] - The company holds a 15% market share in the MCT market, compared to a 72% share in long-term cardiac monitoring [12] Market Data and Key Metrics Changes - iRhythm serves approximately 40,000 primary care physicians, with more than one-third of volume originating from primary care settings [8] - The company is now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share [12] - In the U.K., iRhythm delivered its largest quarter of volume ever and is participating in NHS pilots [12] Company Strategy and Development Direction - The company aims to shift from episodic detection to proactive, integrated, and predictive care, addressing the growing need for long-term continuous monitoring [7][14] - iRhythm's strategy includes expanding margins through operational efficiencies, advancing platform innovation, and scaling international markets [14][26] - The company is focused on maintaining operational excellence and compliance in a rapidly evolving healthcare environment [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable, volume-led growth while expanding profitability in 2026 [26] - The company anticipates revenue for 2026 to be in the range of $870 million to $880 million, representing 16%-18% year-over-year growth [21] - Management highlighted the importance of addressing the challenges in arrhythmia detection and the need for proactive care models [25] Other Important Information - 2025 marked the first year of positive adjusted EBITDA and free cash flow in the company's history [20][21] - The company is actively working on its next-generation MCT device, which is currently under FDA review and expected to be released in the first half of 2027 [11][12] Q&A Session Summary Question: Concerns about chart-derived diagnosis elimination from CMS - Management addressed concerns about chart-derived diagnosis, emphasizing that Zio provides confirmatory diagnoses, which is crucial for integration into workflows and patient records [30][31] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [35][37] Question: Potential tailwind from CMS proposal regarding chart scraping - Management indicated that the confirmatory diagnosis from Zio could serve as a tailwind, as providers seek to bolster documentation in patient records [39][40] Question: AI concerns and customer willingness to perform analysis - Management expressed confidence in their unique data and regulatory position, stating that their platform's closed nature and established workflows would protect against potential AI competition [45][46] Question: Updates on MCT product timeline and enhancements - Management confirmed confidence in the MCT product's timeline for the first half of 2027, highlighting necessary enhancements and the transition to a mobile gateway [51][56] Question: Guidance on partnerships and their scaling - Management noted the addition of incremental partners and emphasized a cautious approach to guidance for the innovative channel business, which is still emerging [65][66]

Core Insights - iRhythm Holdings, Inc. reported strong financial results for Q4 and full year 2025, marking a transformational year with significant revenue growth and positive net income for the first time in its history [4][10]. Financial Highlights Fourth Quarter 2025 - Revenue increased by 27.1% to $208.9 million compared to $164.3 million in Q4 2024, driven by higher demand for Zio Services [5][8]. - Gross profit rose to $148.1 million, up from $115.1 million in Q4 2024, with a gross margin of 70.9%, an improvement from 70.0% [6][8]. - Net income for Q4 2025 was $5.6 million, a significant improvement from a net loss of $1.3 million in Q4 2024 [9][8]. - Adjusted EBITDA was $34.3 million, with an adjusted EBITDA margin of 16.4%, reflecting a $15.0 million increase compared to Q4 2024 [8]. Full Year 2025 - Total revenue for 2025 reached $747.1 million, a 26.2% increase from $591.8 million in 2024 [10][11]. - Gross profit for the year was $527.3 million, up from $407.5 million in 2024, with a gross margin of 70.6%, improving from 68.9% [11]. - The net loss for 2025 was $44.6 million, a $68.7 million improvement compared to a net loss of $113.3 million in 2024 [12][10]. - Free cash flow for 2025 was $34.5 million, marking the first year of positive free cash flow in the company's history [8]. Operational Highlights - The company emphasized the growing demand for Zio across various healthcare sectors, highlighting its ability to provide proactive, data-driven arrhythmia detection [4]. - iRhythm plans to scale its platform globally, advance its product roadmap, and enhance its predictive AI capabilities while maintaining financial discipline [4]. 2026 Guidance - For 2026, iRhythm expects revenue between $870 million and $880 million, with an adjusted EBITDA margin of 11.5% to 12.5%, indicating continued growth and operational efficiency [13].

Core Insights - Teads has appointed Nirali Jain as Managing Director for North America, aiming to enhance its national sales organization and drive growth in the region [1][2] - Jain's expertise in connected TV (CTV) and digital video is expected to help scale new revenue streams and maximize ROI for advertisers [2][3] - Teads positions itself as a leading omnichannel outcomes platform, leveraging predictive AI technology to deliver meaningful business outcomes for marketers [4] Company Overview - Teads is an omnichannel outcomes platform focused on driving full-funnel results for marketers across premium media [4] - The company partners with over 10,000 publishers and 20,000 advertisers globally, employing around 1,700 people across more than 30 countries [4]

Inuvo Inc. Conference Call Summary Company Overview - Inuvo Inc. operates in the ad tech industry, leveraging a proprietary large language model for audience discovery and media activation [1][2] - The company has been in operation for 10 years and is publicly traded on NYSE under the ticker symbol INUV [17] Core Business Model - Inuvo generates revenue through a platform business that services major digital supply chains and agencies, as well as direct marketing to clients [2][3] - The technology is protected by 19 patents and 6 pending patents, emphasizing its proprietary nature [3] Industry Landscape - The U.S. ad market is heavily reliant on programmatic media buying, with 64% of ad dollars funneled through these platforms [4] - The ad tech industry is valued at $220 billion and is experiencing growth, particularly in segments like connected TV and retail media networks [4] - Legacy ad systems are struggling due to privacy concerns and the decline of consumer tracking methods like cookies [4][5] Technological Advantages - Inuvo's technology is designed to operate without personal data, focusing instead on collective interests and intent pathways [9][15] - The IntentKey AI platform analyzes billions of real-time signals to create predictive audience models that refresh every five minutes [9][10] - The technology allows for precise targeting and audience discovery, enabling marketers to reach potential customers before competitors [10][15] Performance Metrics - Inuvo claims a 60% performance advantage over competitive platforms, with a high client retention rate [17] - The company has reported a five-year quarterly compound annual growth rate (CAGR) of 24% through Q2 of the current year [17] - The company is approaching the $100 million revenue mark and has access to $10 million in capital [17][18] Future Growth Strategies - Inuvo plans to expand its client base by adding self-serve clients who can execute their own media buys [18] - The company aims to work more directly with brands, moving upstream in the advertising ecosystem [19] - Targeting high-spending sectors like sports gambling is identified as a significant opportunity for revenue growth [20][21] Key Challenges - The ad tech industry is facing a challenging environment, particularly for agencies, which are being washed out [19] - The company is navigating a complex market landscape but believes its privacy-first approach positions it favorably [19] Conclusion - Inuvo Inc. is positioned as a disruptive force in the ad tech industry, leveraging advanced AI technology to address current market challenges and capitalize on growth opportunities [1][10]

Core Insights - Varonis Systems, Inc. has acquired SlashNext, an AI-native email security provider, to enhance its data breach prevention capabilities [1][4] - The acquisition aims to provide a comprehensive threat detection and response solution, addressing the rise of social engineering attacks across various communication channels [3][4] - The email security market is projected to grow significantly, from $5.2 billion in 2025 to $10.7 billion by 2032, driven by AI-driven phishing and business email compromise (BEC) attacks [5] Company Overview - Varonis is recognized as a leader in data security, focusing on protecting data across various environments, including SaaS, IaaS, and hybrid cloud [14][15] - The company utilizes a cloud-native Data Security Platform that employs AI-powered automation for threat detection and data classification [14][15] Acquisition Details - SlashNext was founded by Atif Mushtaq, a key figure in developing FireEye's malware sandbox technology, and is known for its high detection rates for phishing attacks [2][6] - The acquisition is expected to significantly expand Varonis' total addressable market and enhance the value of its Managed Detection and Response (MDDR) service [4] Financial Outlook - For Q3 2025, Varonis expects revenues between $163.0 million and $168.0 million, reflecting a year-over-year growth of 10% to 13% [7] - For the full year 2025, the company anticipates revenues of $616.0 million to $628.0 million, indicating a year-over-year growth of 12% to 14% [7] - The company also projects an Annual Recurring Revenue (ARR) of $748.0 million to $754.0 million, with a year-over-year growth of 17% [7]

Company Overview - WEBUY GLOBAL LTD is a technology-driven company focused on transforming community e-commerce and travel across Southeast Asia, utilizing predictive AI and personalized recommendations to enhance its group-buy model [5]. Offering Details - The company announced the closing of its offering of 721,918 Class A ordinary shares and pre-funded warrants to purchase up to 100,000 Class A ordinary shares, generating gross proceeds of approximately $3 million before deducting fees and expenses [1][2]. - D. Boral Capital LLC served as the exclusive placement agent for this offering, with legal counsel provided by Ortoli Rosenstatdt LLP for the company and Hunter Taubman Fischer & Li LLC for the placement agent [2]. Regulatory Compliance - The securities were offered under an effective registration statement on Form F-1, which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on June 27, 2025. Multiple post-effective amendments were filed in July 2025, with the final amendment declared effective on July 18, 2025 [3].

Core Insights - iRhythm Technologies has formed a strategic partnership with Lucem Health to enhance early detection of undiagnosed arrhythmias in high-risk patient populations [1][2][3] - The collaboration aims to shift from reactive to proactive healthcare, utilizing AI to identify arrhythmia risks before symptoms manifest [2][3] - The partnership targets over 27 million individuals in the U.S. who could benefit from proactive cardiac monitoring [2][8] Company Overview - iRhythm Technologies is a digital health leader focused on solutions that detect, predict, and prevent disease, utilizing wearable biosensors and cloud-based analytics [18] - Lucem Health specializes in AI-driven early disease detection, aiming to improve clinical outcomes and resource allocation in healthcare [19] Partnership Details - The collaboration will leverage Lucem Health's AI platform and iRhythm's diagnostic services to enable earlier identification of arrhythmia risks [2][3] - The first commercial offering will focus on patients with conditions like Type 2 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, and coronary artery disease [4][6] Clinical Impact - Early pilot testing indicates improved targeting of patient populations at risk for arrhythmias, facilitating earlier clinical engagement [7] - The predictive AI solution is expected to enhance arrhythmia detection among an estimated 27 million undiagnosed patients in the U.S., potentially reducing healthcare resource utilization and costs [8][15] Economic Considerations - Cardiac arrhythmias affect approximately 1 in 20 U.S. adults, and untreated cases can lead to severe health complications, emphasizing the need for early detection [9][11] - Research shows that patients with arrhythmias incur significantly higher healthcare costs, reinforcing the economic case for earlier detection and intervention [13][14]